Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29362288 | 0.80 | HDAC1 (0.48) | MAPTSMN1; SMN2KMT2AMEN1GAA | |
| SCHEMBL6013073 | 0.80 | HDAC1 (0.48) | MAPTSMN1; SMN2KMT2AMEN1GAA | |
| SCHEMBL28604201 | 0.76 | AVPR2 (0.48) | MAPTSMN1; SMN2KMT2AMEN1GAA | |
| SCHEMBL16671108 | 0.76 | CYP11B2 (0.61) | — | |
| SCHEMBL29489948 | 0.76 | CYP11B2 (0.61) | — | |
| Hydrochloric Acid SCHEMBL30640657 | 0.74 | CYP11B2 (0.60) | — | |
| SCHEMBL18997597 | 0.74 | CPT1A (0.46) | MAPTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL29219465 | 0.73 | FGFR4 (0.70) | MAPTNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL3404241 | 0.73 | RAB9A (1.00) | MAPTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL861264 | 0.72 | POLB (0.45) | MAPTGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048130-A1 | ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048130-A1 | ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ITGB6, ITGA6, ITGA2B | MAPT 4795/4885NPC1 3287/4885RAB9A 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.